Related Experiment Video
Updated: May 16, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
COG5-CDG: expanding the clinical spectrum
Daisy Rymen1, Liesbeth Keldermans, Valérie Race
1Centre for Metabolic Diseases, University Hospital Gasthuisberg, Leuven, Belgium.
Orphanet Journal of Rare Diseases
|December 12, 2012
Summary
Five new patients with Conserved Oligomeric Golgi (COG) complex subunit 5 (COG5) deficiency were identified. COG5 deficiency presents a broad spectrum of Congenital Disorders of Glycosylation (CDG) phenotypes, ranging from mild to severe.
Area of Science:
- Molecular biology
- Genetics
- Cell biology
Background:
- The Conserved Oligomeric Golgi (COG) complex is crucial for retrograde Golgi trafficking and proper localization of glycosyltransferases.
- Deficiency in COG subunits causes Congenital Disorders of Glycosylation (CDG), impacting protein glycosylation.
- Mutations in COG subunits 1, 4, 5, 6, 7, and 8 are linked to CDG type II (CDG-II).
Observation:
- The first reported patient with COG5-CDG exhibited a mild to moderate phenotype, including psychomotor retardation and ataxia.
- This study screened CDG-IIx patients for COG5 mutations and compared clinical data.
- Fibroblast Brefeldin A treatment and immunoblotting supported COG5 deficiency diagnoses.
Findings:
- Five new patients with confirmed COG5 deficiency were identified.
- The clinical spectrum of COG5 deficiency is broader than previously thought, ranging from mild to severe.
- Some COG5-CDG patients display overlapping clinical features with COG7-CDG, suggesting potential subunit interactions.
Implications:
- COG5 deficiency presents a wide range of clinical severity in CDG patients.
- Understanding COG subunit interactions is important for diagnosing and characterizing CDG.
- Further research into COG complex function can elucidate mechanisms of glycosylation disorders.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...